Cerus Corporation (CERS)

Market Cap	440.04M
Revenue (ttm)	191.72M
Net Income (ttm)	-31.56M
Shares Out	184.89M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	718,747
Open	2.460
Previous Close	2.380
Day's Range	2.330 - 2.460
52-Week Range	1.210 - 3.080
Beta	1.20
Analysts	Buy
Price Target	3.25 (+36.56%)
Earnings Date	Aug 1, 2024

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 637
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS

Financial Performance

In 2023, Cerus's revenue was $156.37 million, a decrease of -3.51% compared to the previous year's $162.05 million. Losses were -$37.49 million, -12.37% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3.25, which is an increase of 36.56% from the latest price.

Price Target

$3.25

(36.56% upside)

Analyst Consensus: Buy